Status:
UNKNOWN
WT1 Peptid Vaccination in Carcinomas
Lead Sponsor:
Charite University, Berlin, Germany
Conditions:
WT1 Expressing Carcinoma
Eligibility:
All Genders
18+ years
Phase:
PHASE2
Brief Summary
In this trial HLA-A2+ patients with WT1 expressing carcinomas are vaccinated with a peptide from the leukemia associated antigen WT1 together with immunological adjuvants KLH as T-helper protein and G...
Eligibility Criteria
Inclusion
- Metastatic cancer, no standard treatment option
- Resected cancer with minimal residual disease, no standard treatment option
- WT-1 expression
- HLA-A2
Exclusion
- Concurrent chemotherapy
Key Trial Info
Start Date :
April 1 2004
Trial Type :
INTERVENTIONAL
End Date :
Estimated Enrollment :
25 Patients enrolled
Trial Details
Trial ID
NCT00153608
Start Date
April 1 2004
Last Update
February 14 2006
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Hem&Onc Charité CBF
Berlin, Germany, 12200